Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibitionSiker Kimbung, Ingrid Hedenfalk, Astrid Ottosson-Wadlund et al.|Cancer Letters|2012Cited by 44
PD03-07: Breast Cancer Heterogeneity and Treatment Resistance: Clues from Metaplastic Tumors.Brunhilde Felding‐Habermann, SV Vaughn, DM O'Sullivan et al.|Cancer Research|2011Cited by 2